Sydnexis, Inc., ( a biopharmaceutical company focused on pediatric progressive myopia (PPM), today announced topline results from the Phase 3 STAR trial of SYD-101, a proprietary 0.01% atropine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback